Clinical Trials Browser

Phase 2/3 × Dacarbazine × 90 days × Clear all

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

Melanoma